How Often Is Surveillance Endoscopy Repeated for Barrett’s Esophagus? What Sets the Interval

The letter arrives a few weeks after the endoscopy. It says the biopsies showed Barrett’s esophagus, no dysplasia, and that the next procedure is booked for three years from now. Three years. Most people read that twice. Is that reassuring, or is that a long time to leave something that the leaflet calls “precancerous” unwatched?

That tension is the heart of the question of Barrett’s esophagus surveillance, how often it really needs to happen, and why one person is told three years while a neighbor with the same diagnosis hears five. The honest answer is that the interval is not a guess and not a hospital habit. It is set by a short list of measurable things: how long the changed segment is, what the pathologist saw under the microscope, and what has already been treated.

This explainer walks through each of those, using the language your gastroenterologist uses, so the next letter makes sense before you open it.

Barrett's esophagus surveillance: how often is "often enough"?

Barrett’s esophagus is a change in the lining of the lower esophagus, where the normal flat cells are replaced by cells that look more like intestinal lining, usually after years of acid reflux. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes it as a condition that raises the risk of esophageal adenocarcinoma, a cancer of the gland-forming cells, while stressing that most people with Barrett’s never develop that cancer.

Surveillance exists because of that word “most.” If the change toward cancer happened quickly and silently, watching would be pointless. If it never happened, watching would be unnecessary. What actually happens sits in between: the tissue tends to move through recognizable stages, called dysplasia, over years, and those stages can be seen on biopsy before any tumor forms. The 2022 American College of Gastroenterology (ACG) guideline, indexed on PubMed, puts the annual risk of progression to cancer in non-dysplastic Barrett’s at roughly 0.1 to 0.3 percent per year. Low, but not zero, and spread across decades.

“Often enough,” then, means often enough to catch dysplasia while it is still confined to the surface lining and treatable through the endoscope, without putting someone through a sedated procedure every year for a risk that is measured in fractions of a percent. The guidelines resolve that trade-off with intervals of 3 to 5 years for non-dysplastic disease, tightening sharply once dysplasia appears.

One point worth holding onto from the start: the interval is a risk estimate, not a countdown. Nothing in the biology ticks over on the anniversary of your last scope. The number is a planning tool that lets the team concentrate attention where the odds are highest.

What actually happens during a surveillance endoscopy

A surveillance endoscopy is the same upper endoscopy that found the Barrett’s in the first place, done with more deliberate attention to the segment. An endoscope, a thin flexible tube with a camera and light, is passed through the mouth into the esophagus while you are sedated. The Mayo Clinic describes the procedure as typically lasting 15 to 30 minutes, with a recovery period afterward while sedation wears off.

Two things make a surveillance scope different from a routine one. The first is careful inspection. Endoscopists use high-definition white light and often a dye-free enhancement setting that makes surface blood vessels and texture stand out, searching for anything raised, depressed, nodular or differently colored. Visible abnormalities are the highest-yield finding, because dysplasia and early cancer concentrate in them.

The second is systematic biopsy. The ACG guideline recommends the “Seattle protocol”: small tissue samples taken from all four quadrants of the esophageal wall at every 2 cm along the Barrett’s segment, plus targeted samples from any visible lesion. In a 6 cm segment, that can mean a dozen or more biopsies. The samples are tiny, and the esophagus heals from them quickly.

The endoscopist also records the segment using the Prague classification, which notes the length of the circumferential change (the “C” value) and the maximum extent including tongues of tissue (the “M” value). Those two numbers, written as C2M4 for example, are what determine whether your Barrett’s counts as short or long segment, and therefore how often you will be back.

The pathologist’s report arrives separately, usually within a few weeks, and it is that report, not the pictures, that sets the interval.

How do you confirm Barrett's esophagus in the first place?

Barrett’s cannot be confirmed by symptoms, and it cannot be confirmed by looking alone. The NHS notes that heartburn and reflux are common in Barrett’s, but many people with the condition have no symptoms, and many people with severe heartburn never develop it. The diagnosis rests on two things that must both be present.

First, the endoscopist must see salmon-colored lining extending at least 1 cm above the junction where the esophagus meets the stomach. Changes shorter than that are not labeled Barrett’s under the ACG guideline, because such tiny patches are common, hard to measure reproducibly and carry very little risk. Second, biopsies from that lining must show intestinal metaplasia, meaning the pathologist sees goblet cells, the mucus-producing cells typical of intestinal lining, where they do not belong.

This matters for surveillance because an “irregular” or “inflamed” junction without goblet cells does not need the same follow-up, and because a diagnosis made during active inflammation can be unreliable. Reflux damage can make benign cells look worrying. The ACG therefore suggests that if a first endoscopy shows significant esophagitis, surveillance biopsies are best interpreted after the inflammation has settled with acid-suppressing treatment.

People sometimes ask whether a blood test, breath test or scan could do the job. At present, none of them can confirm Barrett’s. Research into swallowable sponge-on-a-string cell collectors and other non-endoscopic sampling methods is active and is mentioned in the ACG guideline as a possible screening tool, but confirmation and surveillance still depend on endoscopy with biopsy. If you were told you “probably” have Barrett’s without a biopsy report, that is a reasonable thing to clarify with your care team before any interval is set.

What sets the interval: the three findings that matter most

Strip away the jargon and the surveillance interval comes down to three questions the team answers after every scope.

How long is the segment? Longer segments contain more cells that have changed, and more cells means more chances for one of them to take the next step. The ACG guideline draws its line at 3 cm: segments under 3 cm are “short,” those 3 cm or longer are “long,” and the long group is scoped more often. The NIDDK and Mayo Clinic both describe segment length as one of the main factors a doctor weighs.

Was there dysplasia, and what grade? Dysplasia is the term for cells that look abnormal under the microscope but have not invaded deeper tissue. Pathologists report it on a ladder: no dysplasia, indefinite for dysplasia, low-grade dysplasia, high-grade dysplasia. Each rung up shortens the interval or moves the conversation toward treatment. Because the distinction between grades is genuinely difficult, the ACG recommends that any dysplasia be confirmed by a second pathologist with gastrointestinal expertise before decisions are made.

Was there a visible lesion? A nodule or raised area is handled differently from flat tissue, regardless of what random biopsies show. The guideline recommends that visible lesions be removed through the endoscope (endoscopic mucosal resection) so the whole area can be examined, since biopsies alone can miss cancer hiding beneath the surface.

Everything else, including age, sex, family history, body weight and smoking, influences whether someone is offered screening in the first place, but once Barrett’s is confirmed, the interval is driven almost entirely by these three findings. Two people of very different ages with identical biopsy reports will usually be given the same interval, at least until later life, where other considerations enter.

Barrett's esophagus surveillance guidelines: the intervals in one table

The table below summarizes the intervals in the 2022 ACG guideline, which is the most widely used framework in the United States. UK and European guidance follows the same logic with modest differences, and the NHS describes a similar pattern of “every few years” for non-dysplastic disease and closer follow-up once dysplasia appears. Your own interval may differ for good reasons; this is the scaffold, not a verdict.

Most recent biopsy finding	Typical next step (ACG 2022)	Why
No dysplasia, segment under 3 cm	Repeat endoscopy in 5 years	Lowest progression risk; fewer changed cells
No dysplasia, segment 3 cm or longer	Repeat endoscopy in 3 years	More tissue at risk
Indefinite for dysplasia	Optimize acid suppression, repeat in 3 to 6 months	Inflammation may be mimicking dysplasia
Low-grade dysplasia (confirmed)	Endoscopic eradication therapy, or surveillance every 12 months if treatment is declined or deferred	Meaningfully higher yearly risk than no dysplasia
High-grade dysplasia	Endoscopic eradication therapy; surveillance every 3 months only if treatment is not pursued	Risk measured in percent per year, not fractions
After complete eradication of high-grade dysplasia or early cancer	Endoscopy at 3 and 6 months, then yearly	Recurrence is possible and is most likely early
After complete eradication of low-grade dysplasia	Endoscopy at 1 year, then every 3 years	Lower recurrence risk than the row above

Notice how the table bends. From no dysplasia to low-grade dysplasia, the interval shrinks from years to a single year. From low to high grade, the default flips from watching to treating. That sharp bend reflects the ACG’s summary of the evidence: the annual risk of cancer rises from around 0.1 to 0.3 percent with no dysplasia to several percent per year with high-grade dysplasia, roughly a twenty-fold difference.

From "indefinite" to high-grade: how dysplasia changes the plan

The middle rungs of the dysplasia ladder generate the most confusion, so they deserve plain language.

Indefinite for dysplasia is not a diagnosis of dysplasia. It is the pathologist saying, honestly, “I cannot tell.” Inflamed, regenerating cells after reflux injury can look alarmingly similar to early dysplasia. The ACG approach is to treat the inflammation, usually by making sure acid suppression is adequate, and look again within 3 to 6 months. Proton pump inhibitors, the class of medicines most often used, work by blocking the acid pumps in stomach-lining cells; the aim is to calm the tissue so the biopsy can be read clearly. Whether and how your prescription changes is a decision for the prescribing clinician. Most “indefinite” results are downgraded to no dysplasia on the repeat scope, though the guideline notes they carry a somewhat higher risk than a clean result and warrant attention.

Low-grade dysplasia is where the evidence is most contested, which is why confirmation by an expert gastrointestinal pathologist is built into the guideline. Studies have found that a large share of community diagnoses of low-grade dysplasia are downgraded on expert review. Once confirmed, the ACG suggests endoscopic eradication therapy, typically radiofrequency ablation, which uses controlled heat to destroy the Barrett’s lining so normal cells can regrow, as the preferred option, with yearly surveillance as the alternative for people who prefer to wait or are not suited to treatment. The choice is shared; neither path is wrong.

High-grade dysplasia tips the balance decisively toward treatment. Here the guideline recommends eradication therapy over surveillance, because the risk of cancer within a few years is substantial and because treatment through the endoscope is now well established. Three-monthly surveillance exists in the guideline mainly for people who cannot or choose not to undergo treatment.

At every rung, a visible lesion changes the sequence: it is removed first, examined fully, and then the plan is set.

How often is surveillance endoscopy repeated for Barrett's esophagus after treatment?

Successful ablation does not end surveillance; it reshapes it. Once biopsies show no remaining intestinal metaplasia, a state the guidelines call complete eradication of intestinal metaplasia, a new clock starts, and its rhythm depends on what was treated.

For people treated for high-grade dysplasia or very early cancer confined to the surface lining, the ACG recommends endoscopy at 3 months and 6 months after eradication, then once a year. The front-loaded schedule reflects where recurrence tends to show up: most recurrences of Barrett’s tissue or dysplasia after ablation appear within the first year or two, and the junction with the stomach is the commonest site. For people treated for low-grade dysplasia, the guideline suggests endoscopy at 1 year, then every 3 years.

Surveillance after ablation looks slightly different from surveillance before it. The endoscopist pays particular attention to the gastroesophageal junction, where small islands of Barrett’s can persist or return, and takes biopsies from the treated zone and the junction even when everything looks normal. Finding a small recurrence is not a failure of treatment; it is the reason the follow-up exists, and recurrences are commonly treated with a further ablation session.

A practical consequence: ablation is a commitment to an ongoing relationship with the endoscopy unit, not a one-time fix. People weighing treatment for low-grade dysplasia sometimes assume that treating now means fewer scopes later. In the first year, it usually means more. Over a decade, the total number may be similar or lower, depending on how the tissue behaves. Your team can walk you through what the schedule would look like in your case.

Acid suppression normally continues after ablation, because ongoing reflux is thought to raise recurrence risk; the specifics belong to your prescriber.

Who is usually offered surveillance, and who is usually asked to wait or not start

Surveillance is offered to people with confirmed Barrett’s esophagus who would be candidates for treatment if dysplasia were found. That second clause carries weight. The purpose of looking is to act on what is seen; if acting would not be possible or wanted, repeated scopes offer little.

Most adults with Barrett’s fall squarely inside the offer. The ACG guideline recommends surveillance for non-dysplastic Barrett’s at the intervals above and suggests it be done with the structured biopsy protocol and high-definition imaging.

Some people are asked to wait before entering a surveillance program:

• Those whose first endoscopy showed active esophagitis, where biopsies may be unreliable until inflammation settles. The repeat scope is a confirmation step, not surveillance yet.
• Those with a segment under 1 cm, which does not meet the definition of Barrett’s and is not routinely surveyed.
• Those whose biopsy showed intestinal metaplasia only at the junction without a visible segment, a finding the guideline does not treat as Barrett’s.

Others are usually not offered ongoing surveillance, or are offered a conversation about stopping, because the balance of benefit and burden shifts:

• People with serious other illnesses that limit life expectancy, where cancer years away is unlikely to be the thing that matters.
• People who could not safely undergo sedated endoscopy or endoscopic treatment.
• People who, fully informed, decide the procedures are not what they want.

Screening, which means looking for Barrett’s in someone not yet diagnosed, is a separate question. The ACG suggests considering a one-time screening endoscopy for people with chronic reflux plus several risk factors such as male sex, age over 50, white race, obesity, smoking or a family history, while advising against screening the general population. If you are reading this because a relative has Barrett’s, that is the conversation to have.

When to stop surveillance for Barrett's esophagus

There is no birthday at which surveillance automatically ends, and the guidelines deliberately avoid setting one. Instead, the ACG frames stopping as a decision about whether a future finding could still change what happens to you.

The reasoning is arithmetic as much as medicine. With non-dysplastic Barrett’s progressing at roughly 0.1 to 0.3 percent per year according to the ACG’s review, the chance of developing cancer over the next five years is low. For a healthy 60-year-old with decades ahead, those small yearly risks accumulate into something worth monitoring. For someone with advanced heart or lung disease, or in their late 80s with multiple conditions, the probability that Barrett’s becomes the dominant health problem within their remaining years is much smaller, while the burden and risks of sedated procedures are, if anything, higher.

Guidelines therefore suggest that the decision to continue be revisited as people age and as other health conditions develop, weighing life expectancy, fitness for treatment and personal preference. Many clinicians raise the question in a person’s mid-to-late 70s if biopsies have stayed non-dysplastic for years, though practice varies and the evidence for a precise cutoff is weak. Where dysplasia has been found or treated, the calculation differs and surveillance generally continues longer.

Stopping is not the same as abandonment. Someone who stops surveillance still has access to care, and new symptoms such as difficulty swallowing or unexplained weight loss would still prompt an endoscopy. What stops is the scheduled, symptom-free looking.

If you have been told your surveillance is being discontinued, it is reasonable to ask why, what the estimated risk is, and what would bring you back. If you would rather continue and are well enough for treatment, that preference is a legitimate part of the decision and worth stating plainly.

Barrett's esophagus biopsy results explained: the days and weeks after a scope

The first day after a surveillance endoscopy is mostly about the sedation. Mayo Clinic advises arranging someone to take you home and avoiding driving, work decisions and alcohol for the rest of the day. A mild sore throat, bloating from the air used to inflate the esophagus, and a sense of fullness are common and usually settle within a day. Biopsy sites may cause a small amount of blood-streaking in saliva or a dark fleck in stool once; more than that is worth reporting.

Eating usually resumes within hours, starting with something soft and cool. Most people are back to normal routines the next day.

The pathology report typically takes one to three weeks, longer if a second pathologist is asked to review. When it arrives, it will contain several items that are easy to misread:

• “Intestinal metaplasia present” simply confirms Barrett’s is still there. It is expected in surveillance and is not a worsening.
• “Negative for dysplasia” is the result that keeps you on the 3- or 5-year schedule.
• “Indefinite for dysplasia” leads to a repeat scope in months, not a treatment decision.
• “Low-grade” or “high-grade dysplasia” should prompt a conversation about expert review and options, not an immediate conclusion about cancer.
• Prague C and M values describe length; a small change from one scope to the next usually reflects measurement variation rather than growth.

Reports also often mention the stomach and duodenum, since the whole upper tract is examined. Findings such as mild gastritis are common and separate from the Barrett’s plan.

Your team will usually contact you with the result and the next date. If weeks pass with no word, a call to the clinic is appropriate; results occasionally wait on a review that has not been communicated.

Can lifestyle or "natural treatments" stretch the interval?

People searching for natural treatments for Barrett’s esophagus are usually asking two questions: can I make this go away, and can I make it safer. The evidence answers them differently.

On the first, the answer is no. The NIDDK and Mayo Clinic are consistent that no diet, supplement or herbal product has been shown to reverse Barrett’s tissue back to normal lining. Claims that a particular food, oil or regimen “heals” Barrett’s are not supported by trials, and following them in place of surveillance means losing the one intervention with evidence behind it. Herbal products also sometimes interact with prescribed medicines, which is another reason to mention anything you take to your team.

On the second, lifestyle has a real but supporting role. Measures that reduce reflux, such as maintaining a healthy weight, not smoking, limiting alcohol, avoiding late large meals and raising the head of the bed, are recommended by the NHS and Mayo Clinic because reflux drives the inflammation that makes the tissue unstable and biopsies harder to read. Smoking and obesity are also independent risk factors for progression in the ACG’s review. These steps improve symptoms and may modestly influence risk; they do not change the guideline interval, because the interval is tied to what the biopsy shows.

Acid-suppressing medicines sit between these categories. Proton pump inhibitors reduce acid production and are recommended by the ACG for people with Barrett’s, with observational evidence suggesting an association with lower progression risk, though trial evidence is limited and the guideline is cautious about overstating it. The decision to use them, and for how long, belongs with the prescribing clinician, and nothing here should prompt anyone to start or stop a medicine on their own.

What lifestyle changes cannot do is substitute for the scope. What they can do is make each scope more likely to give a clear answer.

What people often get wrong about Barrett's surveillance

“Barrett’s means I will get cancer.” It does not. The Cleveland Clinic and Mayo Clinic both emphasize that most people with Barrett’s never develop esophageal cancer; the yearly risk without dysplasia is a fraction of a percent. Surveillance exists precisely because the risk is small but real.

“A five-year interval means they are not taking it seriously.” A long interval is the guideline’s response to a low-risk finding, short segment and clean biopsies. It is a sign of reassurance, not neglect.

“My segment got longer, so it is spreading.” Length measurements vary by a centimeter or so between operators and between scopes. A C2M3 becoming C3M3 is more often a measurement difference than growth. Patterns over several scopes matter more than a single change.

“Low-grade dysplasia is basically early cancer.” It is a risk marker, and a famously hard one to read. The ACG builds in expert review because many initial diagnoses are downgraded.

“If my heartburn has gone, the Barrett’s has gone.” Symptoms and tissue are not linked in that way. Many people with Barrett’s have no heartburn at all, and treatment that settles symptoms does not remove the metaplasia.

“Ablation means I am done with scopes.” Treated Barrett’s needs its own follow-up schedule, front-loaded in the first year, because recurrence is possible.

“Natural remedies can replace surveillance.” Nothing swallowed has been shown to reverse the tissue change. Lifestyle helps reflux; it does not replace looking.

“Barrett’s takes decades, so I can skip a cycle.” The tissue often does take years to form, but the point of the interval is that dysplasia can arise at any time within it. Skipping a scheduled scope means the next look happens at double the intended gap.

Questions to ask your care team

A surveillance appointment is short, and the result letter is shorter. These questions help turn both into something you can use.

• What were my Prague C and M measurements, and does my segment count as short or long?
• Did the biopsies follow the four-quadrant protocol along the whole segment, and how many samples were taken?
• Was any dysplasia reported, and if so, has a second gastrointestinal pathologist reviewed the slides?
• Were there any visible lesions, and were they removed or just biopsied?
• Which guideline interval applies to me, and is my scheduled date the same or different? If different, why?
• If my result is “indefinite for dysplasia,” what will be done about reflux before the repeat scope, and when exactly will it be?
• If low-grade dysplasia is confirmed, what are the realistic options for me, and what would the surveillance schedule look like on each path?
• How will I receive my results, and whom do I call if I have not heard within three weeks?
• Are there symptoms between scopes that should bring me back sooner?
• Looking ahead, at what point would you expect us to revisit whether to continue surveillance at all?
• Is anyone in my family likely to benefit from a conversation about screening?

Write the answers down or ask for them in the clinic letter. The two numbers worth memorizing are your segment length and your last dysplasia grade; with those, every future letter will make sense, and you will be able to tell quickly if a proposed interval sits where the guidelines would put it. If it does not, asking is not a challenge to your team; good clinicians expect it and can usually explain the reasoning in a sentence.

When to call your doctor

Surveillance is designed for a condition that usually causes no symptoms, so new symptoms between scheduled scopes are a reason to make contact rather than wait for the next date. The NHS, Mayo Clinic and MedlinePlus list the following as signs that need prompt assessment, regardless of how recent your last endoscopy was:

• Difficulty swallowing, food feeling stuck, or needing to change what you eat because solids will not go down.
• Pain on swallowing.
• Unintentional weight loss.
• Vomiting blood, or vomit that looks like coffee grounds.
• Black, tarry stools, which can indicate bleeding higher in the digestive tract.
• Chest pain, especially if new or unlike your usual heartburn; chest pain should always be assessed urgently because heart causes need to be excluded.
• Persistent hoarseness, a chronic cough or repeated vomiting without an obvious cause.

In the first 24 to 48 hours after a surveillance endoscopy, seek urgent care for severe or worsening chest, neck or upper abdominal pain, fever, repeated vomiting, vomiting blood, black stools, or difficulty breathing. These are uncommon but can indicate bleeding from a biopsy site or, very rarely, a tear in the esophageal wall, and they need same-day assessment.

Less urgent but still worth a call: not receiving your biopsy result within three weeks, a result letter you do not understand, a proposed interval that seems to differ from what was discussed, or new heartburn that is not controlled despite following the plan you were given. Managing reflux well between scopes is part of the plan, and your clinician would rather hear about breakthrough symptoms than find inflamed tissue at the next look.

Every decision described in this article, from the interval itself to whether to treat dysplasia or stop surveillance, sits with the gastroenterology team who knows your biopsies. This explainer is a map of the territory; they hold the compass.

Frequently asked questions

Why is my Barrett's esophagus endoscopy every 3 years when a friend's is every 5?

The difference is almost always segment length. Under the 2022 ACG guideline, Barrett’s without dysplasia measuring 3 cm or longer is surveyed every 3 years, while segments under 3 cm are surveyed every 5 years, because longer segments contain more changed tissue and carry a somewhat higher risk. A past finding of indefinite or low-grade dysplasia can also keep someone on a shorter cycle.

When to stop surveillance for Barrett's esophagus?

Guidelines do not set a fixed age; they suggest stopping when a future finding would be unlikely to change what happens to you. That usually means limited life expectancy from other illness, inability to undergo endoscopic treatment, or a personal decision after discussion. Clinicians often revisit the question in a person’s mid-to-late 70s if biopsies have stayed non-dysplastic, but the decision is individual.

How do you confirm Barrett's esophagus?

Confirmation requires both an endoscopy showing salmon-colored lining extending at least 1 cm above the junction with the stomach and biopsies showing intestinal metaplasia, meaning goblet cells where they do not belong. Symptoms alone cannot confirm it, and neither can blood tests or scans. If active inflammation is present, the diagnosis may need repeating once reflux has been treated and the tissue has settled.

How long does it take for Barrett's esophagus to form?

There is no precise figure. Barrett’s is thought to develop over years of repeated acid exposure, which is why it is most often diagnosed in people over 50 with long-standing reflux. Patient-education sources such as Cleveland Clinic put the share of people with chronic reflux who develop Barrett’s at roughly 10 to 15 percent. Once present, progression to dysplasia, if it happens, also usually unfolds over years.

What are some natural treatments for Barrett's esophagus?

No natural treatment has been shown to reverse Barrett’s tissue, and relying on one instead of surveillance means losing the only approach with evidence behind it. What lifestyle can do is reduce reflux: keeping a healthy weight, not smoking, limiting alcohol, avoiding large late meals and raising the head of the bed are all supported by the NHS and Mayo Clinic. Mention any supplements to your team, since some interact with prescribed medicines.

Do Barrett's esophagus surveillance guidelines differ between countries?

The logic is shared, with modest differences in numbers. The US ACG guideline uses 3 and 5 years for long and short non-dysplastic segments; UK and European guidance uses similar length-based intervals, sometimes slightly shorter for long segments, and all shorten follow-up sharply when dysplasia appears. Your team applies the guideline used in your health system, and small differences between countries do not mean one group is unsafe.

What does "indefinite for dysplasia" mean on my biopsy report?

It means the pathologist saw abnormal-looking cells but could not tell whether they represent true dysplasia or the effects of inflammation from reflux, which can mimic it. The usual response is to make sure acid suppression is adequate and repeat the endoscopy within 3 to 6 months. Many of these results are downgraded to no dysplasia on the repeat scope, though they carry somewhat more risk than a clean result.

Is Barrett's esophagus surveillance painful or risky?

The procedure is done under sedation and most people remember little of it; a mild sore throat and bloating for a day are the usual aftermath. Serious complications such as significant bleeding from biopsy sites or a tear in the esophageal wall are rare. Mayo Clinic describes upper endoscopy as a generally safe procedure, and the small risks are weighed against the benefit of detecting dysplasia early.

Will I still need surveillance after radiofrequency ablation?

Yes. Once biopsies show complete eradication of intestinal metaplasia, a new schedule begins. For high-grade dysplasia or early cancer, the ACG recommends endoscopy at 3 and 6 months, then yearly; for low-grade dysplasia, at 1 year and then every 3 years. Recurrences are most common early and near the junction with the stomach, and they are usually treatable with further ablation.

Does the length of my Barrett's segment change from scope to scope?

Small changes are common and usually reflect measurement variation between endoscopists, the position of the scope, or how much the esophagus is distended, rather than true growth. A difference of about a centimeter in Prague C or M values is generally not significant on its own. A consistent trend across several scopes, or crossing the 3 cm threshold, is what might prompt a change in interval.

References

• NIDDK: Barrett's Esophagus
• Cleveland Clinic: Barrett's Esophagus
• MedlinePlus Medical Encyclopedia: Barrett esophagus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.